



Comprehensive Cancer Center Zurich

EUROPEAN CENTRAL NERVOUS SYSTEM METASTASIS CONFERENCE

February 12-13, 2025, 9.00 a.m. – 5.00 p.m.
Grosser Hörsaal Ost, hybrid



Interested in more events of the
[Comprehensive Cancer Center Zurich?](#)

Please visit our website:



Credits:
TBD

If you need a certificate
please send an e-mail to
cccz@usz.ch

Program Thursday, 12th of February 2026

9.15 a.m. **Welcome Coffee, Registration**

9.45 a.m. **Opening Remarks**

Matthias Guckenberger, University Hospital Zurich
Matthias Preusser, MedUni Wien
Emilie Le Rhun, University Hospital Zurich

Session 1: Pre-clinical research – Anna Berghoff, Tobias Weiss

10.00 a.m. **Neural and vascular influences on brain metastasis**

Frank Winkler, Heidelberg, DE

10.30 a.m. **Biological monitoring of melanoma and response prediction**

Mitchell Levesque, Zurich, CH

11.00 a.m. **Pro-Contra Topic Animal Models**

Pro: Amanda Fitzpatrick, London, UK
Contra: Andreas Wicki, University Hospital Zurich

11.10 a.m. **Panel Discussion Animal Models**

11.20 a.m. **Coffee Break**

Session 2: Novel Diagnostic Approaches – Nathalie Albert, Roland Goldbrunner

11.40 a.m. **Methylation profiling for brain metastases**

Andreas von Deimling, Heidelberg, DE

12.10 p.m. **New MRI approaches for diagnosis and follow-up of CNS metastases**

Marion Smits, Erasmus Rotterdam

12.40 p.m. **Pro-Contra Screening MRI**

Pro: Nicolin Hainc, Zurich, CH
Contra: Volkmar Müller, Hamburg, DE

12.50 p.m. **Panel Discussion Screening MRI**

12.40 p.m. **Lunch Break**

Session 3: Clinical Trials in Progress – Matthias Preusser, Johanna Mangana

1.40 p.m. **Selected Abstract 1**

1.50 p.m. **Selected Abstract 2**

2.00 p.m. **Panel Discussion**

2.10 p.m. **Selected Abstract 3**

2.20 p.m. **Selected Abstract 4**

2.30 p.m. **Selected Abstract 5**

2.40 p.m. **Panel Discussion**

Session 4: Surgery – Carlo Serra, Michael Weller

2.50 p.m. **Neurosurgical Approaches in CNS Metastases: where do we go?**

Roland Goldbrunner, Cologne, DE

3.20 p.m. **Neurosurgical Trials in CNS Metastases: is it the way to go?**

Johny Duerinck, Brussels, BE

3.50 p.m. **Pro-Contra Topic LITT**

Pro: Rachel Grossmann, M.D. Professor of Neurosurgery, Rambam Health Care Campus Technion, Haifa, IS

Contra: Tomas Kazda, Brno, CZ

4.00 p.m. **Panel Discussion LITT**

4.10 p.m. **Coffee Break**

Session 5: Clinical Trial Highlights – Sanjay Popat, Caroline Robert

4.30 p.m. **TUXEDO-3**

The trial presented by its PI: Matthias Preusser, Vienna, AT

4.40 p.m. **Discussant:** Volkmar Müller, Hamburg, DE

4.45 p.m. **Panel Discussion**

5.00 p.m. **IT-IO**

The trial presented by its PI: Emilie Le Rhun, Zurich, CH

5.10 p.m. **Discussant:** Johanna Mangana, Zurich, CH

5.15 p.m. **Panel Discussion**

5.30 p.m. **Final remarks of the day**

Matthias Preusser, Vienna AT – Emilie Le Rhun, Zurich, CH

Program Friday, 13th of February 2026

Session 6: Translational Research – Dieta Brandsma, Mitch Levesque

- 8.30 a.m.** **Next steps for histo-molecular and methylation use**
Felix Sahm, Heidelberg, DE
- 9.00 a.m.** **The EVIDENCE-BM story**
Berend Snijder, Basel CH
- 9.30 a.m.** **Pro-Contra Topic Liquid Biopsy**
Pro: Tobias Weiss, Department of Neurology, University of Zurich and University Hospital Zurich
Contra: Giulia Berzero, Milan, IT
- 9.40 a.m.** **Panel Discussion**
- 9.50 a.m.** **Coffee Break**
- Session 7: Radiotherapy and Radioligand Therapy – Lizza Hendricks, , Matthias Guckenberger**
- 10.10 a.m.** **Re-irradiation: how many targets? what is a target?**
Luis Schiappacasse, Lausanne, CH
- 10.40 a.m.** **RT first or Systemic pharmacotherapy first?**
Giuseppe Minniti, Roma, IT
- 11.10 a.m.** **Can PET help to define the target to irradiate?**
Ilinca Pop, Freiburg, DE
- 11.40 a.m.** **Strategies to develop RLT trials in CNS Metastases**
Nathalie Albert, Munich, DE
- 12.10 p.m.** **Pro-Contra Topic Radioligand Therapy**
Pro: Dr. Nelleke Tolboom, Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht, NL
Contra: Dieta Brandsma, Amsterdam, NL
- 12.20 p.m.** **Panel Discussion**
- 12.30 p.m.** **Lunch Break**

Session 8: Patient's Voices – Michael Weller

- 1.10 p.m.** **The Challenge of CNS Metastases for Patients and Caregivers**
Helen Bulbeck, Isle of Wight, UK

Session 9: Trial Design – Rupert Bartsch

- 1.30 p.m.** **Smart Safety Planning and SAE Management in Clinical Research**
Regina Grossmann, Zurich, CH
- 1.50 p.m.** **New Endpoints in CNS Metastases Trials**
Michael Weller, Zurich, CH
- 2.10 p.m.** **Panel Discussion**

- 2.30 p.m.** **Coffee Break**

Session 10: Pharmacotherapy Advances – Matthias Preusser, Emilie Le Rhun

- 2.50 p.m.** **Systemic Therapy in Breast Cancer BM**
Assoc.-Prof. PD Dr. Rupert Bartsch, Department of Medicine 1, Division of Oncology, Medical University Vienna, Austria
- 3.10 p.m.** **Lung Cancer – Sanjay Popat, London, UK**
- 3.30 p.m.** **Melanoma – Caroline Robert, Paris, FR**
- 3.50 p.m.** **Leptomeningeal Metastases – Roberta Rudà, Turin, IT**
- 4.10 p.m.** **Palliative Care – Caroline Hertler, Zurich, CH**
- 4.30 p.m.** **Pro-Contra Topic Ex vivo drug testing**
Pro: Anna Berghoff, Vienna, AT
Contra: Lizza Hendrikks, Maastricht, NL
- 4.40 p.m.** **Panel discussion Ex vivo drug testing**
- 4.50 p.m.** **Final Remarks**
Matthias Preusser, Emilie Le Rhun